Repare Therapeutics Inc.
reparerx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 14, 2025. Its latest SEC filing is a SCHEDULE 13G/A from May 14, 2026.
10-Q for Q3 FY2025, filed Nov 14, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops targeted cancer drug candidates for patients with genetically defined cancers, using genetic screening to find weaknesses in tumor cells.
10-K for FY2024, filed Mar 3, 2025We are a clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development…View ↗
Who Were Their Customers?
Pharmaceutical companies such as Roche and Bristol-Myers Squibb partner with Repare on drug licenses and research programs; Repare has not established a commercial sales or distribution operation.
10-K for FY2024, filed Mar 3, 2025In June 2022, the Company entered into a collaboration and license agreement (the “Roche Agreement”) with Hoffmann-La Roche Inc. and F.…View ↗
In May 2020, we entered into a collaboration and license agreement, or the BMS Agreement, with Bristol-Myers Squibb Company, or…View ↗
Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We have established a…View ↗
Did Revenues Turn Into Profits?
No. It lost $84.7M in .
10-K for FY2024, filed Mar 3, 2025
−$93.5MView ↗
10-K for FY2024, filed Mar 3, 2025
−$84.7MView ↗
10-K for FY2024, filed Mar 3, 2025
−$76.4MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 14, 2025
$3.3MView ↗
- ▲ Now profitable
- vs −$34.4M in Q3 FY2024
-
Jan 28, 2026
Xeno completed its acquisition of Repare
Repare became Xeno’s wholly owned subsidiary, and it requested that Nasdaq suspend trading and delist the shares.
Sources
8-K, filed Jan 28, 2026
In connection with the consummation of the Transaction, the Company (i) notified the Nasdaq Capital Market LLC (“Nasdaq”) of the…View ↗
-
Dec 29, 2025
Gilead acquired assets tied to the RP-3467 program
Gilead acquired assets mainly related to RP-3467 and assumed certain liabilities under transferred contracts.
Sources
8-K, filed Dec 29, 2025
On December 23, 2025 (the “Closing Date”), Repare Therapeutics Inc. (the “Company”) and Gilead Sciences, Inc. (“Gilead”) entered into an…View ↗
-
Jul 16, 2025
Debiopharm licensed lunresertib
Debiopharm took over sponsorship of the ongoing combination trial and future development activities for lunresertib.
Sources
8-K, filed Jul 16, 2025
On July 15, 2025, Repare Therapeutics Inc. (the “Company”) entered into an exclusive worldwide license agreement (the “Agreement”) with…View ↗
Who Did They Compete With?
Competes with Loxo Oncology, Blueprint Medicines, SpringWorks Therapeutics, Black Diamond Therapeutics, Deciphera Pharmaceuticals, Tango Therapeutics, Zentalis Pharmaceuticals, Turning Point Therapeutics, Exelixis, AstraZeneca, GlaxoSmithKline, Pfizer, Bayer, Merck Serono, Schrodinger, Artios Pharma, IDEAYA Biosciences, Impact Therapeutics, Aprea Therapeutics, and Shanghai De Novo Pharmatech
10-K for FY2024, filed Mar 3, 2025We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of precision…View ↗
Loading...
